Tolerance Issues in the Use of Somatostatin Analogs in Palliative Care

Clare, Charlotte; Bennett, Mike

doi:10.1016/s0885-3924(01)00376-1

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cependant le rapport coût/bénéfice de ce choix est à évaluer : pour les posologies habituellement proposées, le coût de la Sandostatine ® est 25 fois plus important que celui du Scoburen ® (80,48 Q TTC les 600 µg de Sandostatine ® et 3,66 Q TTC les 120 mg de Scoburen ® , tarifs hospitaliers 2004). Il est égale-ment possible d'utiliser la Sandostatine ® pour traiter des épi-sodes subocclusifs à répétition [10] retardant ainsi le passage en occlusion constituée. La forme LP paraît alors plus indiquée à raison d'une injection de 20 à 30 mg par voie intramusculaire par mois.…”

Section: Discussionunclassified

Traitement de l'occlusion intestinale sur carcinose péritonéale. Étude prospective à propos de 80 cas

Arvieux

Laval

Mestrallet

et al. 2005

Annales de Chirurgie

View full text Add to dashboard Cite

Section: Discussionunclassified

Traitement de l'occlusion intestinale sur carcinose péritonéale. Étude prospective à propos de 80 cas

Arvieux

Laval

Mestrallet

et al. 2005

Annales de Chirurgie

View full text Add to dashboard Cite

“…Octreotide is a somatostatin analogue that reduces intestinal and pancreas secretion and gastrointestinal motility, biliary contraction, and intestinal edema. 20,33 Octreotide may be administered by subcutaneous bolus or continuous subcutaneous infusion. Its duration of activity is approximately 6 to 12 hours, with an average half-life elimination of 1.8 hours, thus necessitating a multiple daily dosing schedule.…”

Section: Somatostatin Analoguesmentioning

confidence: 99%

MASCC Multidisciplinary Evidence-Based Recommendations for the Management of Malignant Bowel Obstruction in Advanced Cancer

Madariaga

Lau

Ghoshal

et al. 2021

Preprint

View full text Add to dashboard Cite

PurposeTo provide evidence based recommendations on the management of malignant bowel obstruction (MBO) for patients with advanced cancer.MethodsThe Multinational Association for Supportive Care in Cancer (MASCC) MBO study group conducted a systematic review of databases (inception to March 2021) to identify studies about patients with advanced cancer and MBO that reported on the following outcomes: symptom management, bowel obstruction resolution, prognosis, overall survival and quality of life. The review was restricted to studies published in English but no restrictions were placed on publication year, country and study type. As per the MASCC Guidelines Policy, the findings were synthesized to determine the levels of evidence to support each MBO intervention and, ultimately, the graded recommendations and suggestions.ResultsThe systematic review identified 17,656 published studies and 397 selected for the guidelines. The MASCC study group developed a total of 25 evidence-based suggestions and recommendations about management of MBO-related nausea and vomiting, bowel movements, pain, inflammation, bowel decompression and nutrition. Expert consensus-based guidance about advanced care planning and psychosocial support is also provided.ConclusionThis MASCC guideline provides comprehensive, evidence-based recommendations about MBO management for patients with advanced cancer.

show abstract

MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer

Madariaga

Lau²,

Ghoshal³

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

Purpose To provide evidence-based recommendations on the management of malignant bowel obstruction (MBO) for patients with advanced cancer. Methods The Multinational Association for Supportive Care in Cancer (MASCC) MBO study group conducted a systematic review of databases (inception to March 2021) to identify studies about patients with advanced cancer and MBO that reported on the following outcomes: symptom management, bowel obstruction resolution, prognosis, overall survival, and quality of life. The review was restricted to studies published in English, but no restrictions were placed on publication year, country, and study type. As per the MASCC Guidelines Policy, the findings were synthesized to determine the levels of evidence to support each MBO intervention and, ultimately, the graded recommendations and suggestions. Results The systematic review identified 17,656 published studies and 397 selected for the guidelines. The MASCC study group developed a total of 25 evidence-based suggestions and recommendations about the management of MBO-related nausea and vomiting, bowel movements, pain, inflammation, bowel decompression, and nutrition. Expert consensus-based guidance about advanced care planning and psychosocial support is also provided. Conclusion This MASCC Guideline provides comprehensive, evidence-based recommendations about MBO management for patients with advanced cancer.

show abstract

Tolerance Issues in the Use of Somatostatin Analogs in Palliative Care

Cited by 3 publications

References 5 publications

Traitement de l'occlusion intestinale sur carcinose péritonéale. Étude prospective à propos de 80 cas

Traitement de l'occlusion intestinale sur carcinose péritonéale. Étude prospective à propos de 80 cas

MASCC Multidisciplinary Evidence-Based Recommendations for the Management of Malignant Bowel Obstruction in Advanced Cancer

MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer

Contact Info

Product

Resources

About